Clinical research
The company hopes to resume the trials following an assessment of data.
“Reducing the risk that muscle-invasive urothelial cancer will recur after surgery is very difficult, and we are disappointed that we were not able to significantly prolong disease-free survival,” said Levi Garraway, Genentech’s chief medical officer and head of Global Product Development.
There were plenty of clinical trial announcements this week. Here’s a look.
As the J.P. Morgan Healthcare Conference winds down for 2020, one of the big topics was the general lack of big deals. Still, there were some general trends and for today, some news.
The biosimilar candidate, IBI305, completed a Phase III study in China and was granted Priority Review by that country’s National Medical Products Administration.
Companies from across the globe provide updates to their business and pipeline.
The company’s chief executive officer, Ludwig Hantson, admits it’s a longshot.
In 2016, Soon-Shiong announced the Cancer Moonshot and set a 2020 deadline, claiming he would transform the war on cancer.
What’s New at the J.P. Morgan Life Healthcare Conference?
AbbVie reported that its Skyrizi met both primary and all ranked secondary endpoints in its Phase III trial that went head-to-head with Novartis’ Cosentyx in plaque psoriasis.
PRESS RELEASES